Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist gegebenenfalls nur via VPN oder Shibboleth (DFN-AAI) möglich. mehr Informationen...
Ergebnis 13 von 142

Details

Autor(en) / Beteiligte
Titel
Improved Trimethylangelicin Analogs for Cystic Fibrosis: Design, Synthesis and Preliminary Screening
Ist Teil von
  • International journal of molecular sciences, 2022-10, Vol.23 (19), p.11528
Ort / Verlag
Basel: MDPI AG
Erscheinungsjahr
2022
Quelle
EZB Electronic Journals Library
Beschreibungen/Notizen
  • A small library of new angelicin derivatives was designed and synthesized with the aim of bypassing the side effects of trimethylangelicin (TMA), a promising agent for the treatment of cystic fibrosis. To prevent photoreactions with DNA, hindered substituents were inserted at the 4 and/or 6 positions. Unlike the parent TMA, none of the new derivatives exhibited significant cytotoxicity or mutagenic effects. Among the synthesized compounds, the 4-phenylderivative 12 and the 6-phenylderivative 25 exerted a promising F508del CFTR rescue ability. On these compounds, preliminary in vivo pharmacokinetic (PK) studies were carried out, evidencing a favorable PK profile per se or after incorporation into lipid formulations. Therefore, the selected compounds are good candidates for future extensive investigation to evaluate and develop novel CFTR correctors based on the angelicin structure.
Sprache
Englisch
Identifikatoren
ISSN: 1422-0067, 1661-6596
eISSN: 1422-0067
DOI: 10.3390/ijms231911528
Titel-ID: cdi_doaj_primary_oai_doaj_org_article_ac4097f0c602425aa4b1f0e52423b399

Weiterführende Literatur

Empfehlungen zum selben Thema automatisch vorgeschlagen von bX